Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Technol Assess Health Care. 2003 Fall;19(4):731-7.

Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers.

Author information

1
Department of Health Management and Policy, School of Public Health, Saint Louis University, MO 63104, USA.

Abstract

OBJECTIVES:

This study estimates the cost-effectiveness (CE) of the adjunctive use of hyperbaric oxygen (HBO2) therapy in the treatment of diabetic ulcers based on the payer's and societal perspectives.

METHODS:

The study population was a hypothetical cohort of 1,000 patients sixty years of age with severe diabetic foot ulcers. A decision tree model was constructed to estimate the CE of HBO2 therapy in the treatment of diabetic ulcers at years 1, 5, and 12. Scenario and one-way sensitivity analyses were also undertaken to identify parameters that may significantly influence the estimates.

RESULTS:

The CE model estimated that the incremental cost per additional quality-adjusted life year (QALY) gained at years 1, 5, and 12, was dollar 27,310, dollar 5,166, and dollar 2,255, respectively.

CONCLUSIONS:

The study results indicate that HBO2 therapy in the treatment of diabetic ulcers is cost-effective, particularly based on a long-term perspective. However, the results are limited by the clinical studies that provide the basis of the CE estimation.

PMID:
15095781
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center